Targeted Delivery Platforms for the Treatment of Multiple Sclerosis

Area of Science:

• Neuroscience
• Immunology
• Nanotechnology

Background:

• Multiple sclerosis (MS) is a CNS neurodegenerative disease with significant patient disability.
• Current treatments for MS aim to protect nerves but comprehensive improvement remains a challenge.
• Developing novel therapeutic strategies for MS is a critical research area.

Purpose of the Study:

• To review and summarize particle systems and targeted therapies for MS treatment.
• To discuss the potential of these advanced approaches in preclinical and clinical MS stages.
• To highlight the role of nanotechnology in enhancing MS management.

Main Methods:

• Review of existing literature on nanoscale platforms for MS.
• Analysis of targeted therapies including nanoparticles, antibodies, peptides, nucleic acids, and engineered cells.
• Discussion of neuroprotective strategies in MS treatment.

Main Results:

• Nanoscale platforms show potential for improved diagnosis and treatment of MS.
• Significant progress has been made in developing neuroprotective strategies using nanoparticles, antibodies, peptides, and aptamers.
• Targeted therapies offer enhanced effectiveness compared to conventional MS treatments.

Conclusions:

• Nanoscale platforms and targeted therapies represent a promising frontier in MS treatment.
• These innovative approaches can potentially improve the effectiveness of conventional therapies for MS.
• Future advancements in targeted delivery may lead to new strategies for progressive MS recovery.